A major Phase III trial has delivered promising results for patients battling one of the world’s deadliest cancers, with global pharma giant AstraZeneca announcing a significant leap forward in liver cancer treatment outcomes.
High-level data from the EMERALD-3 trial revealed that a four-drug combination led by Imfinzi (durvalumab) and Imjudo (tremelimumab), alongside lenvatinib and transarterial chemoembolisation (TACE), significantly delayed disease progression in patients with unresectable hepatocellular carcinoma (HCC), compared to TACE alone.
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Early signals also point to a survival benefit, with interim overall survival (OS) data trending higher in the combination therapy group.
Patients received the STRIDE regimen—Single Tremelimumab Regular Interval Durvalumab—either with or without lenvatinib, before and during TACE. Even without formal statistical testing at this stage, the STRIDE-plus-TACE arm demonstrated strong trends toward improved outcomes across both PFS and OS.
The findings could reshape treatment for HCC, the most common form of liver cancer, which affects hundreds of thousands of patients eligible for embolisation each year. Despite being a standard-of-care procedure, TACE alone often fails to prevent disease progression or recurrence within months.
Ghassan Abou-Alfa, principal investigator of the trial, said, “Dual immunotherapy with durvalumab and tremelimumab in the STRIDE regimen represents a meaningful advance for patients with embolisation-eligible liver cancer, who currently lack systemic treatment options to keep their cancer from progressing or recurring, with a trend of improving survival. EMERALD-3 shows we can now significantly reduce the risk of disease progression with STRIDE as the immunotherapy backbone alongside lenvatinib and TACE.”
The results build on earlier success from the HIMALAYA Phase III trial, which established the STRIDE regimen as an effective option in advanced disease.
Susan Galbraith said: “EMERALD-3 now shows that bringing the dual immunotherapy STRIDE regimen earlier, alongside TACE and lenvatinib, can further improve outcomes in earlier-stage liver cancer. This builds on the HIMALAYA Phase III trial data in patients with advanced, unresectable disease, where the STRIDE regimen has already demonstrated durable overall survival benefit. We are discussing these positive data with global regulatory authorities while awaiting the final results from the key secondary endpoints.”
The trial is ongoing, with researchers continuing to track overall survival and other key outcomes. Early safety data indicate the combination therapy remains consistent with known profiles, raising hopes that a new frontline standard of care could be within reach.
